Why this matters
The role of aggressive local treatment for metastatic sites in Ewing sarcoma remains incompletely defined.
Systemic therapy is central to treatment, but patients may present with multiple bone or soft-tissue metastases, raising two practical questions: whether SBRT can safely control individual metastatic lesions and whether treating all known sites contributes meaningfully to long-term outcome.
AEWS1221 provides prospective Children's Oncology Group data addressing both questions. The strongest evidence concerns local control after SBRT. The survival findings associated with comprehensive metastasis-directed therapy are striking, but require more cautious interpretation because local therapy allocation itself was not randomized.
Study design
AEWS1221 was a prospective randomized Children's Oncology Group trial in patients with newly diagnosed metastatic Ewing sarcoma.
After consolidation therapy, definitive local treatment with surgery, SBRT, or conventionally fractionated radiotherapy was recommended for all metastatic sites identified at diagnosis.
For unresected bone metastases smaller than 5 cm, SBRT was prospectively evaluated.
The SBRT regimen was:
- 40 Gy in 5 fractions
- 35 Gy in 5 fractions when treatment overlapped with whole-lung irradiation
Baseline imaging, response imaging, and radiotherapy plans underwent central review.
The analysis evaluated:
- local recurrence after SBRT
- local recurrence after conventionally fractionated RT
- local recurrence without local treatment
- event-free survival and overall survival according to whether patients received comprehensive metastasis-directed therapy
Among 298 eligible patients, 169 remained event-free through consolidation and had discrete metastatic disease beyond bone marrow. Local therapy information was available for 167 patients.
Eighty-five patients had bone metastases. Seventy-four were considered eligible for SBRT, and 44 actually received SBRT.
Key results
SBRT was successfully delivered in 32 of 44 patients who received it.
At 3 years, cumulative local recurrence in treated bone metastases was:
- 2% with any SBRT
- 9.5% with conventionally fractionated RT only
- 33% without local therapy
The confidence intervals were wide:
- SBRT: 95% CI 0.2-10%
- CFRT only: 95% CI 2-27%
- no local therapy: 95% CI 9-60%
Suspected treatment-related toxicity did not differ significantly among SBRT, conventional RT, and no RT:
- 50%
- 48%
- 33%
- p=0.6
The patient-level outcomes according to comprehensive metastasis-directed therapy were markedly different.
Three-year event-free survival was:
- 59% with comprehensive metastasis-directed therapy
- 26% without comprehensive metastasis-directed therapy
- p<0.001
Three-year overall survival was:
- 67.9% with comprehensive metastasis-directed therapy
- 27.8% without comprehensive metastasis-directed therapy
- p=0.002
Interpretation
The clearest finding from this analysis is that SBRT can achieve excellent local control of small bone metastases in selected patients with metastatic Ewing sarcoma.
A 3-year local recurrence rate of only 2% after SBRT is clinically notable, particularly compared with the 33% observed at sites receiving no local therapy.
The larger question is whether comprehensive treatment of all metastatic sites improves survival.
The numerical differences are substantial. Three-year EFS was 59% versus 26%, and OS was 67.9% versus 27.8% in patients who did and did not receive comprehensive metastasis-directed therapy.
However, those survival results should not be interpreted as randomized evidence that comprehensive local therapy caused the improvement.
Patients who remained eligible for and received treatment to all metastatic sites may differ systematically from those who did not. Disease burden, anatomical feasibility, treatment response, performance status, or other clinical factors could influence both the likelihood of receiving comprehensive therapy and subsequent survival.
The authors themselves describe these as univariate findings, with further analyses planned.
The local-control data therefore provide the more robust immediate message: SBRT appears feasible and highly effective for appropriately selected small bone metastases in metastatic Ewing sarcoma.
The survival association strengthens the rationale for comprehensive local treatment, but does not yet establish its causal effect.
Limitations
The analysis includes only patients who remained event-free through consolidation, introducing an important selection step before assessment of local therapy.
SBRT was not delivered to all eligible lesions or patients, and successful delivery was achieved in 73% of patients who received SBRT.
There were also protocol deviations, including both minor and major SBRT deviations.
Most importantly, comprehensive metastasis-directed therapy was not randomized. The EFS and OS comparisons are therefore subject to selection bias and confounding.
The number of patients in individual local therapy groups was relatively small, resulting in wide confidence intervals around local recurrence estimates.